Stock prices for Novo Nordisk dropped precipitously Friday after a last-minute announcement from the Biden administration ...

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

That news was welcome to rival Eli Lilly and Co., which makes weight-loss drugs Zepbound and Mounjaro that compete with Novo Nordisk’s Wegovy and Ozempic. Tomi Kilgore is MarketWatch's deputy ...

When it comes to weight loss drugs, Ozempic has ... almost 1500% vs. its price in Europe, and 1000% for Wegovy. Regardless, investors are much more concerned with future stock performance over ...

The list price for a one-month supply of Ozempic costs close to $1,000 without insurance or manufacturer coupons. According to CMS data, Medicare Part D spending on Ozempic was more than $4.6 ...

The continent's flagship Stoxx 600 gauge tumbled 1.7%. Ozempic maker Novo, which is the index's biggest component, slumped 17% after the company posted disappointing data for its experimental ...

the popular drug sold by Novo Nordisk as Ozempic for diabetes and Wegovy for weight loss, is among a group of widely used medicines selected by the U.S. government for the next round of price ...

The price negotiations for the additional 15 drugs selected will be handled by the incoming Trump administration and almost assures billions of dollars in savings for taxpayers. Ozempic and Wegovy ...

The GLP-1 market is currently dominated by semaglutide (Ozempic and Wegovy) produced by Novo Nordisk Shares of GE HealthCare Technologies are trading higher because of an upgrade. There has been ...